Accessibility Menu
 
Adaptive Biotechnologies logo

Adaptive Biotechnologies

(NASDAQ) ADPT

Current Price$14.17
Market Cap$2.14B
Since IPO (2019)-66%
5 Year-64%
1 Year+61%
1 Month-9%

Adaptive Biotechnologies Financials at a Glance

Market Cap

$2.14B

Revenue (TTM)

$276.98M

Net Income (TTM)

$59.50M

EPS (TTM)

$-0.40

P/E Ratio

-34.86

Dividend

$0.00

Beta (Volatility)

1.98 (High)

Price

$14.17

Volume

70,601

Open

$14.38

Previous Close

$14.17

Daily Range

$13.95 - $14.50

52-Week Range

$6.67 - $20.76

ADPT: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Adaptive Biotechnologies

Industry

Life Sciences Tools and Services

Employees

624

CEO

Chad Robins, MBA

Headquarters

Seattle, WA 98109, US

ADPT Financials

Key Financial Metrics (TTM)

Gross Margin

74%

Operating Margin

-21%

Net Income Margin

-21%

Return on Equity

-28%

Return on Capital

-14%

Return on Assets

-12%

Earnings Yield

-2.87%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$2.14B

Shares Outstanding

153.98M

Volume

70.60K

Short Interest

0.00%

Avg. Volume

2.00M

Financials (TTM)

Gross Profit

$205.62M

Operating Income

$57.12M

EBITDA

$29.85M

Operating Cash Flow

$45.99M

Capital Expenditure

$2.96M

Free Cash Flow

$48.95M

Cash & ST Invst.

$226.98M

Total Debt

$280.58M

Adaptive Biotechnologies Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$71.68M

+51.0%

Gross Profit

$53.46M

+81.7%

Gross Margin

74.58%

N/A

Market Cap

$2.14B

N/A

Market Cap/Employee

$3.46M

N/A

Employees

619

N/A

Net Income

$13.58M

+59.7%

EBITDA

$6.43M

+75.6%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$53.60M

-140.3%

Accounts Receivable

$50.37M

+20.7%

Inventory

$9.82M

+16.4%

Long Term Debt

$267.02M

+237.4%

Short Term Debt

$13.56M

+32.5%

Return on Assets

-11.60%

N/A

Return on Invested Capital

-13.51%

N/A

Free Cash Flow

$1.42M

+111.3%

Operating Cash Flow

$2.06M

+116.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ZLABZai Lab Limited
$18.29+4.69%
BEAMBeam Therapeutics Inc.
$23.12-3.47%
IRONDisc Medicine, Inc.
$62.55+4.93%
MLYSMineralys Therapeutics, Inc.
$24.62+7.60%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$7.31-0.04%
TERNTerns Pharmaceuticals
$52.86+0.06%
TQQQProShares Trust - ProShares UltraPro Qqq
$44.39+0.02%
UGROUrban-gro
$36.29+4.17%

Questions About ADPT

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.